Journal of Rheumatic Diseases

Table. 1.

Baseline characteristics of patients obtained serum sample (n=153)

Variable Value
Demographic parameters
Age (yr) 66.35±8.22
Sex, female 107 (69.9)
Body mass index 23.40±2.95
Ever smoker 39 (25.5)
Pack-years of smoking 32.05±10.88
RA parameters
RF (IU/mL) 244.24±500.53
Anti-CCP (units/mL) 199.62±166.86
DAS28-ESR 3.99±1.47
DAS28-CRP 3.10±1.42
HAQ-DI 0.68±0.76
PGA* 36.41±26.38
Duration of RA (yr) 8.08±8.14
Medication use (ever)
Glucocorticoids 145 (94.8)
Methotrexate 99 (64.7)
Hydroxychloroquine 98 (64.1)
Sulfasalazine 91 (59.5)
Leflunomide 57 (37.3)
Tacrolimus 49 (32.0)
Etanercept 21 (13.7)
Infliximab 8 (5.2)
Adalimumab 11 (7.2)
Tocilizumab 10 (6.5)
Abatacept 13 (8.5)
Pulmonary function test
FEV1, % of predicted 92.26±21.52
FVC, % of predicted 85.56±16.60
DLCO, % of predicted 71.89±19.47
Six minute walk test, meter 342.71±112.11
CT grade
Grade 1 (0%∼25%) 86 (56.2)
Grade 2 (26%∼50%) 46 (30.1)
Grade 3 (51%∼75%) 15 (9.8)
Grade 4 (75%∼100%) 6 (3.9)
Serum levels
TNF-α (pg/mL) 3.46±8.54
IL-6 (pg/mL) 6.09±24.31
MMP-7 (pg/mL) 7,524.35±4,481.77
SP-D (pg/mL) 9,721.65±7,148.10
KL-6 (units/mL) 598.35±545.76

Values are presented as mean±standard deviation or number (%). RA: rheumatoid arthritis, RF: rheumatoid factor, Anti-CCP: anti-cyclic citrullinated peptide antibody , DAS28: disease activity score of 28 joints, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, HAQ-DI: health assessment questionnaire-disability index, PGA: patient global assessment, FEV1: forced expiratory volume in one second, FVC: forced vital capacity, DLCO: diffusing capacity for carbon monoxide, TNF-α: tumor necrosis factor α, IL-6: interleukin 6, MMP-7: matrix metallopeptidase 7, SP-D: surfactant protein D, KL-6: Krebs von den Lungen 6. *PGA ranges from 0 to 100 mm.

J Rheum Dis 2021;28:234~241 https://doi.org/10.4078/jrd.2021.28.4.234
© J Rheum Dis